Valérie Durieux

Dr. Valérie Durieux

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in Radiology
Verified
Journal Article
Closed access
VDValérie Durieux
Valérie Durieux
PGPierre Alain Gevenois
Pierre Alain Gevenois
It is essential to simultaneously consider multiple indicators when evaluating the quality of any scientific output and to refer to expert opinion to interpret them. Bibliometrics is a set of mathematical and statistical methods used to analyze and measure the quantity and quality of books, articles, and other forms of publications. There are three types of bibliometric indicators: quantity indicators, which measure the productivity of a particular researcher; quality indicators, which measure the quality (or “performance”) of a researcher’s output; and structural indicators, which measure connections between publications, authors, and areas of research. Bibliometric indicators are especially important for researchers and organizations, as these measurements are often used in funding decisions, appointments, and promotions of researchers. As more and more scientific discoveries occur and published research results are read and then quoted by other researchers, bibliometric indicators are becoming increasingly important. This article provides an overview of the currently used bibliometric indicators and summarizes the critical elements and characteristics one should be...

25 May 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
ASArnaud Scherpereel
Arnaud Scherpereel
IOIsabelle Opitz
Isabelle Opitz
TBThierry Berghmans
Thierry Berghmans
IPIoannis Psallidas
Ioannis Psallidas
MGMarkus Glatzer
Markus Glatzer
PPPaul Martin Putora
Paul Martin Putora
The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for Radiotherapy and Oncology (ESTRO) task force brought together experts to update previous 2009 ERS/ESTS guidelines on management of malignant pleural mesothelioma (MPM), a rare cancer with globally poor outcome, after a systematic review of the 2009–2018 literature. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach. The evidence syntheses were discussed and recommendations formulated by this multidisciplinary group of experts. Diagnosis: pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally via image-guided percutaneous needle biopsy in cases of pleural symphysis or poor performance status. Pathology: standard staining procedures are insufficient in ∼10% of cases, justifying the use of specific markers, including BAP-1 and CDKN2A ( p16 ) for the separation of atypical mesothelial proliferation from MPM. Staging: in the absence of a uniform, robust and validated staging system, we advise using the most recent 2016 8th TNM (tumour, node, metastasis) classification, with an algorithm for pre-therapeutic assessment. Monitoring: patient's performance status, histological subtype and tumour volume are the main prognostic factors of clinical importance in routine MPM management. Other potential parameters should be recorded at baseline and reported in clinical trials. Treatment: (chemo)therapy has limited efficacy in MPM patients and only selected patients are candidates for radical surgery. New promising targeted therapies, immunotherapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres.

1 December 2018 in Lung Cancer
Verified
Journal Article
Closed access
TBThierry Berghmans
Thierry Berghmans
VDValérie Durieux
Valérie Durieux
SHStéphane Holbrechts
Stéphane Holbrechts
CJChristiane Jungels
Christiane Jungels
JLJean-Jacques Lafitte
Jean-Jacques Lafitte
NGNicolas Girard
Nicolas Girard

1 December 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
NGNiccolò Giaj-Levra
Niccolò Giaj-Levra
MLMatteo Giaj Levra
Matteo Giaj Levra
VDValérie Durieux
Valérie Durieux
SNSilvia Novello
Silvia Novello
BBBenjamin Besse
Benjamin Besse
TBThierry Berghmans
Thierry Berghmans

13 November 2025 in European Respiratory Journal
Verified
Journal Article
Closed access
ABAlessandro Brunelli
Alessandro Brunelli
GHGeorgia Hardavella
Georgia Hardavella
RHRudolf M Huber
Rudolf M Huber
TBThierry Berghmans
Thierry Berghmans
AFArmin Frille
Armin Frille
TBTorsten Gerriet Blum
Torsten Gerriet Blum
A multidisciplinary panel of lung cancer experts with a special interest in functional evaluation of lung cancer patients, and lung cancer patient representatives, has been facilitated by the European Society of Thoracic Surgeons and the European Respiratory Society to provide healthcare professionals with practical and up-to-date recommendations for the assessment of patients’ fitness for curative intent treatments for lung cancer. The panel formulated four PICO (population, intervention, comparison and outcomes) questions and seven complementary narrative questions. Both types of questions were assigned to groups of at least two experts. A medical librarian conducted the literature searches, and the authors selected relevant studies based on predefined inclusion criteria. Risk of bias was assessed using the QUIPS (Quality in Prognosis Studies) tool. Data were summarised and the certainty of evidence was assessed with GRADE (Grading of Recommendations, Assessment, Development and Evaluations) and the Evidence to Decisions framework was used to formulate recommendations. A series of multidisciplinary recommendations was formulated about the utilisation of pulmonary function tests, split lung function values, exercise tests, cardiologic testing, and the role of prehabilitation, sublobar resections, risk scores and comorbidities in selecting patients for curative intent treatment.

17 November 2022 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
TBTorsten Gerriet Blum
Torsten Gerriet Blum
RMRebecca L. Morgan
Rebecca L. Morgan
VDValérie Durieux
Valérie Durieux
Joanna Chorostowska-WynimkoJoanna Chorostowska-Wynimko
Joanna Chorostowska-Wynimko
DBDavid R. Baldwin
David R. Baldwin
TBThierry Berghmans
Thierry Berghmans
This European Respiratory Society guideline is dedicated to the provision of good quality recommendations in lung cancer care. All the clinical recommendations contained were based on a comprehensive systematic review and evidence syntheses based on eight PICO (Patients, Intervention, Comparison, Outcomes) questions. The evidence was appraised in compliance with the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Evidence profiles and the GRADE Evidence to Decision frameworks were used to summarise results and to make the decision-making process transparent. A multidisciplinary Task Force panel of lung cancer experts formulated and consented the clinical recommendations following thorough discussions of the systematic review results. In particular, we have made recommendations relating to the following quality improvement measures deemed applicable to routine lung cancer care: 1) avoidance of delay in the diagnostic and therapeutic period, 2) integration of multidisciplinary teams and multidisciplinary consultations, 3) implementation of and adherence to lung cancer guidelines, 4) benefit of higher institutional/individual volume and advanced specialisation in lung cancer surgery and other procedures, 5) need for pathological confirmation of lesions in patients with pulmonary lesions and suspected lung cancer, and histological subtyping and molecular characterisation for actionable targets or response to treatment of confirmed lung cancers, 6) added value of early integration of palliative care teams or specialists, 7) advantage of integrating specific quality improvement measures, and 8) benefit of using patient decision tools. These recommendations should be reconsidered and updated, as appropriate, as new evidence becomes available.